Cardiovascular Systems to Present at Two September Investor Conferences
September 07 2010 - 4:16PM
Business Wire
Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device
company developing and commercializing innovative, interventional
treatment systems for vascular disease, will present at two
upcoming health care conferences in New York: the Robert W. Baird
Health Care Conference at the St. Regis New York, and the Fifth
Annual JMP Securities Health Care Conference at the New York
Palace. President and Chief Executive Officer David L. Martin and
Chief Financial Officer Laurence L. Betterley will provide an
overview of the company and its growth opportunities.
WHEN:
Robert W. Baird Health Care
Conference
Tuesday, Sept. 14; 10 a.m. EST St. Regis New York New York
Fifth Annual JMP Securities
Health Care Conference
Tuesday, Sept. 28; 1 p.m. EST New York Palace New York
WEBCAST:
To listen to a live webcast of
either presentation, go to the investor information section of the
company’s Web site, www.csi360.com, and click on the respective
webcast icon.
If you have any difficulty
accessing the webcast, please contact Mick Forgey: (612) 455-1789;
mforgey@psbpr.com
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
interventional treatment systems for vascular disease. The
company’s Diamondback 360® and Diamondback Predator 360™ PAD
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. As many as 12 million
Americans suffer from peripheral arterial disease (PAD), which is
caused by the accumulation of plaque in peripheral arteries
(commonly the pelvis or leg) reducing blood flow. Symptoms include
leg pain when walking or at rest, and can lead to tissue loss and
eventually limb amputation. In August 2007, the U.S. FDA granted
510(k) clearance for the use of the Diamondback 360° as a therapy
for PAD, and CSI commenced a U.S. product launch in September 2007.
Since then, nearly 30,000 procedures have been performed using the
Diamondback 360° in leading institutions across the United States.
For more information visit the company’s Web site at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2023 to Jun 2024